Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism

International Journal of Cardiology

Volumn 167, Issue 3, 2013, Pages 910-916

  Biscetti, Federico ^a   Pecorini, Giovanni ^a   Straface, Giuseppe ^b   Arena, Vincenzo ^c   Stigliano, Egidio ^c   Rutella, Sergio ^d   Locatelli, Franco ^d   Angelini, Flavia ^a   Ghirlanda, Giovanni ^a   Flex, Andrea ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b SANTA MARIA GORETTI HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Angiogenesis; Cilostazol; Vascular endothelial growth factor; VEGF

Indexed keywords

CILOSTAZOL; DIMETHYL SULFOXIDE; GRANULOCYTE COLONY STIMULATING FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; HINDLIMB; LIMB PERFUSION; MALE; MOUSE; MUSCLE ISCHEMIA; NONHUMAN; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; UPREGULATION;

ANGIOGENESIS; CILOSTAZOL; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; DISEASE MODELS, ANIMAL; HINDLIMB; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; TETRAZOLES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATOR AGENTS;

EID: 84880923164     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.103     Document Type: Article

References (36)

1. A. Reunanen, H. Takkunen, and A. Aromaa Prevalence of intermittent claudication and its effect on mortality Acta Med Scand 211 1982 249 256
2. W.R. Hiatt Medical treatment of peripheral arterial disease and claudication N Engl J Med 344 2001 1608 1621
3. D.L. Dawson, B.S. Cutler, and W.R. Hiatt A comparison of cilostazol and pentoxifylline for treating intermittent claudication Am J Med 109 2000 523 530
4. Y. Ikeda, M. Kikuchi, and H. Murakami Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study Arzneimittelforschung 37 1987 563 566
5. M.B. Elam, J. Heckman, and J.R. Crouse Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication Arterioscler Thromb Vasc Biol 18 1998 1942 1947
6. T. Kamiya, and S. Sakaguchi Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities Arzneimittelforschung 35 1985 1201 1203
7. A. Hashimoto, G. Miyakoda, Y. Hirose, and T. Mori Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism Atherosclerosis 189 2006 350 357
8. M.E. O'Donnell, S.A. Badger, and M.A. Sharif The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease Eur J Vasc Endovasc Surg 37 2009 326 335
9. F. Biscetti, G. Straface, D. Pitocco, F. Zaccardi, G. Ghirlanda, and A. Flex Peroxisome proliferator-activated receptors and angiogenesis Nutr Metab Cardiovasc Dis 19 2009 751 759
10. J.W. Ji, F. Mac Gabhann, and A.S. Popel Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise Am J Physiol Heart Circ Physiol 293 2007 H3740 H3749
11. T.M. Lee, S.F. Su, and J.J. Hwang Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6 Atherosclerosis 158 2001 471 476
12. F. Biscetti, G. Straface, and V. Arena Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation Cardiovasc Diabetol 8 2009 49
13. Y.L. Ye, W.Z. Shi, and W.P. Zhang Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries Eur J Pharmacol 557 2007 23 31
14. T. Iba, A. Kidokoro, M. Fukunaga, K. Takuhiro, M. Ouchi, and Y. Ito Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice Shock 26 2006 522 526
15. N. Urao, H. Inomata, and M. Razvi Role of nox2-based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia Circ Res 103 2008 212 220
16. M. Nakano, K. Satoh, and Y. Fukumoto Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice Circ Res 100 2007 662 669
17. S. Rutella, L. Pierelli, and G. Bonanno Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells Blood 100 2002 2562 2571
18. R.L. Kendall, G. Wang, and K.A. Thomas Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR Biochem Biophys Res Commun 226 1996 324 328
19. F. Biscetti, E. Gaetani, and A. Flex Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism Diabetes 57 2008 1394 1404
20. F. Biscetti, G. Straface, and R. De Cristofaro High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism Diabetes 59 2010 1496 1505
21. I. Airoldi, E. Di Carlo, and C. Cocco Endogenous IL-12 triggers an antiangiogenic program in melanoma cells Proc Natl Acad Sci U S A 104 2007 3996 4001
22. J. Koga, T. Matoba, and K. Egashira Soluble Flt-1 gene transfer ameliorates neointima formation after wire injury in flt-1 tyrosine kinase-deficient mice Arterioscler Thromb Vasc Biol 29 2009 458 464
23. G.P. Clagett, M. Sobel, M.R. Jackson, G.Y. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 609S 626S
24. M.A. Howell, M.P. Colgan, R.W. Seeger, D.E. Ramsey, and D.S. Sumner Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study J Vasc Surg 9 1989 691 696 [discussion 6-7]
25. M.E. O'Donnell, S.A. Badger, M.A. Sharif, I.S. Young, B. Lee, and C.V. Soong The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease J Vasc Surg 49 2009 1226 1234
26. T. Tanaka, T. Ishikawa, M. Hagiwara, K. Onoda, H. Itoh, and H. Hidaka Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle Pharmacology 36 1988 313 320
27. W.S. Weintraub The vascular effects of cilostazol Can J Cardiol 22 Suppl. B 2006 56B 60B
28. P. Robless, D.P. Mikhailidis, and G.P. Stansby Cilostazol for peripheral arterial disease Cochrane Database Syst Rev 2008 [CD003748]
29. T. Nakamura, H. Houchi, and A. Minami Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta Life Sci 69 2001 1709 1715
30. S. Goto Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding Atheroscler Suppl 6 2005 3 11
31. K. Jujo, M. Ii, and D.W. Losordo Endothelial progenitor cells in neovascularization of infarcted myocardium J Mol Cell Cardiol 45 2008 530 544
32. N. Werner, S. Kosiol, and T. Schiegl Circulating endothelial progenitor cells and cardiovascular outcomes N Engl J Med 353 2005 999 1007
33. A. Hori, R. Shibata, K. Morisaki, T. Murohara, and K. Komori Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism Eur J Vasc Endovasc Surg 43 2012 62 65
34. Y. Ohki, B. Heissig, and Y. Sato Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils FASEB J 19 2005 2005 2007
35. A.K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signalling - in control of vascular function Nat Rev Mol Cell Biol 7 2006 359 371
36. H. Ota, M. Eto, S. Ogawa, K. Iijima, M. Akishita, and Y. Ouchi SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis J Atheroscler Thromb 17 2010 431 435